Ibuprofen brand names

Ibuprofen

The non-steroidal anti-inflammatory and analgesic drug ibuprofen is sold under a wide variety of brand names across the world. The most common being Advil, Motrin, and Nurofen.^{[1][2][3][4][5]}

Nurofen

Nurofen

Founder	Boots Healthcare International
Headquarters	Bath, United Kingdom
Services	Medication
Parent	Reckitt Benckiser

Nurofen is the brand name of a range of pain-relief medication made by Reckitt Benckiser. Introduced in 1983, the Nurofen brand was acquired following Reckitt Benckiser's acquisition of Boots Healthcare in 2005. The brand is primarily marketed and sold in the United Kingdom, other parts of Europe, South Africa, Australia and New Zealand.

There are 11 variants of Nurofen, all of which contain ibuprofen as an active ingredient.^[6] The ibuprofen is variously formulated as the free acid or the lysine salt, or may alternatively be in the form of a gel cap. In some cases these are marketed as being useful for treating specific types of pain such as back pain or period pain. The primary difference among the various formulations is speed and duration of ibuprofen absorption. According to the UK Medicines and Healthcare Products Regulatory Agency, the form of ibuprofen in Nurofen Tension Headache (ibuprofen lysine) is absorbed nearly twice as fast as the form in Neurofen Period Pain (ibuprofen free acid), with the former reaching peak blood concentrations in 38 minutes compared to 80 minutes for the latter.^[7]

Some variants of Nurofen contain other active ingredients; for example, Nurofen Cold & Flu contains the non-sedating decongestant pseudoephedrine. Others are advertised as being targeted for specific pain types (for example "Period Pain Relief").

In Australia Nurofen products claiming to be specific to certain types of pain were ordered to be removed from sale, as they were not different from cheaper non-specific Nurofen brands.

Nurofen Plus

Nurofen Plus is a pain relief medication based on codeine and ibuprofen.^[8] It contains 12.8 mg of codeine phosphate (a mild opioid analgesic) and 200 mg of ibuprofen,^[8] which is an NSAID. Nurofen Plus is the only product in the Nurofen range that contains codeine.

The original tablet was manufactured in two equal parts, joined together and coated. One part would contain the 12.8 mg of codeine phosphate and the other part contained 200 mg of ibuprofen. The tablets could be forcefully split for recreational use of codeine. Such drugs have a potential for misuse because they are available freely to the public.^[9]

2011 product recall

In August 25, 2011 it was reported that several packs of Nurofen Plus were found to contain Seroquel XR—a anti-psychotic drug used to treat schizophrenia—in Boots stores across London.^[10][11][12] The next day, a safety alert was issued by the Medicines and Healthcare Products Regulatory Agency (MHRA). Pharmacists were told to check each package of Nurofen Plus to look for anti-psychotic drugs. There were three batches of Nurofen Plus which were affected by the alert. Reckitt Benckiser, manufacturer of Nurofen Plus, said that it did not know where the drugs had been switched. The product was re-released in cellophane-sealed packs.^[13]

Christopher McGuire was later found guilty of one count of contaminating goods and two of administering a noxious substance and jailed for 18 months. McGuire cost the manufacturers £2.4m and saved himself £7 when he put anti-psychotic drugs in empty packets of the painkiller. The scheme involved asking for Nurofen Plus at a pharmacy counter and then attempting to pay for it with a card he knew would be declined. This created a sufficient distraction for McGuire to discreetly swap the contaminated packet for the fresh one and walk away.^[14]

Misleading advertising

The Australian consumer advocate Choice awarded Nurofen a Shonky^[15] in 2010 for charging more for 'targeted' products, all of which had the same active ingredient as the base product.

In 2012 the Australian Therapeutic Goods Administration upheld a complaint that Nurofen's advertising of different products for different pain was "misleading or likely to be misleading" and ordered that "any representation that refers to two or more Nurofen products that contain equivalent quantities of ibuprofen and include the same product specific indications on the Australian Register of Therapeutic Goods must clearly indicate, in the body of the advertisement, that the two products can be used for the same purposes and are interchangeable (or words to that effect)."^[16]

In April 2013 the Australian consumer affairs television programme The Checkout ran a story about Nurofen's claims about targeting specific pain. Edelman, the PR company for Reckitt Benckiser provided a statement, some of which was used in the program. Included in the information provided by Edelman were photocopies of some 'sciencey looking documents' that confirmed that Ibuprofen was 'Non-selective' ^[17] In March 2015 the Australian Competition and Consumer Commission (ACCC) launched proceedings against Reckitt Benckiser for misleading advertising for its targeted pain range. In December 2015 the Federal Court of Australia found that Reckitt Benckiser, which makes Nurofen, had misled consumers with its "Nurofen Specific pain range", and ordered that all Nurofen specific pain products be removed from retail sale within 3 months.^[18] A spokeswoman for Reckitt Benckiser argued that, "[This] specific-pain range" was intended "to help consumers navigate their pain relief options, particularly within the grocery environment where there is no healthcare professional to assist decision making."^[19] The ACCC said that the products were found to be "no more effective at treating the type of pain described on its packaging than any of the other Nurofen specific pain products", and sold for almost twice the price.^[20] Specific pain range painkillers include Nurofen Back Pain, Nurofen Period Pain, Nurofen Migraine Pain and Nurofen Tension, and all contain the "same active ingredient, 342 milligrams of ibuprofen lysine."^[19]

Following the 2015 Australian decision, the UK Advertising Standards Authority (ASA) said that it was investigating earlier complaints about a television advertisement for Nurofen Express, alleged to be misleading as it implied that the medicine targeted muscles in the head.^[21]

List of brands

References